Somalogic

Measure high- and somalogic proteins confidently with superior sensitivity, high specificity, and proven reproducibility. See the science.

SomaLogic, Inc. SomaLogic monitors health and disease through the analysis of protein concentration changes in biological samples. As of , the commercial version of the SomaScan platform could identify and quantify 1, protein analytes simultaneously. In , SomaLogic partnered with Agilent Technologies to distribute SomaScan systems to American research and educational institutions. It also signed a development deal with Quest Diagnostics to create a blood test for early-stage, non-small-cell lung cancer. SomaLogic has a long-term partnership with the Novartis Institutes for BioMedical Research, with Novartis taking an ownership stake in SomaLogic in as a part of the extension of their initial agreement. Contents move to sidebar hide.

Somalogic

SomaLogic Inc SomaLogic is a protein biomarker discovery and clinical diagnostics company. It provides SOMAscan assay, a proteomics technology that compares protein levels in individuals with and without various health conditions and identify biological signals of proteins to develop predictive state tests for disease, health and wellness. It also offers its SOMAscan technology available to healthcare researchers for conducting clinical protein measurements and biomarker discovery. A database of medical devices that are in the process to get approved for sale around the world. Devices that are in development, through to those in the approval process are included. A database of clinical trials planned, currently ongoing, completed, suspended, withdrawn, and terminated in countries around the world. History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events. Have you found what you were looking for? Contact the team or request a demo to find out how our data can drive your business forward. Visit Corporate Site. Sign in. Book a demo. Industries We Cover Your curated industry news round-up. Subscribe now. Who We Serve Build your customized intelligence tool.

This organization has no public members.

Nasdaq: LAB , driven by a bold purpose — Unleashing tools to accelerate breakthroughs in human health , today announced that it has completed its merger with SomaLogic, creating a leading provider of differentiated multi-omics tools for research. Each SomaLogic stockholder will receive 1. As a larger well-capitalized company, we have greater capacity to self-fund future growth initiatives and accelerate research insights across the industry, better serving our customers and delivering sustainable long-term growth for our shareholders. We are focused on ensuring a smooth transition and achieving our stated commitments. The combined company is poised to realize significant benefits as a multi-omic technology leader, targeting large, high growth markets with a diverse portfolio of life sciences tools that power industry-leading throughput and data quality.

SomaScan Panels offer flexibility in choosing your combination of protein targets from a library of 7, proteins. Pick your analytes. SomaScan Panels are fully automated, so the assay is ready to run as soon as you select your targets. The assay also measures proteins in low and high abundance within the same sample, providing more information and insight from every test. Learn more about SomaScan Panels. Learn more.

Somalogic

The SomaScan Platform is a high-plex , high-throughput proteomics technology developed by SomaLogic that revolutionizes how researchers gain insights into protein biology and protein-protein interactions. As a single solution for discovery, validation, and development, the SomaScan Platform is pioneering proteomics. The platform:. Go in-depth on how the SomaScan Assay works. The SomaScan Platform provides the ability to detect the most proteins over a broad dynamic range without sacrificing reproducibility , sensitivity, or specificity.

Panda peng menu

Read Edit View history. At the time, SomaLogic felt the move would help it establish SomaScan as a clinical diagnostics platform, for which it would need access to large patient cohorts. The company developed more than 30 tests based on the SomaScan system, commercializing 16 of them as laboratory-developed tests, but none ever contributed meaningful revenues. Python 11 3 1 1 Updated Mar 1, ProViz is a basic data visualization and analysis tool developed at SomaLogic. Not for use in diagnostic procedures. On Sept. At the same time, Katz said his group has observed slightly higher precision in its measurements using SomaScan. Many researchers contacted by GenomeWeb declined to speak on the record for the story, but none said that one company's platform clearly outperformed the other and most said they found both useful in their work. What's Popular? Graphics types are biased towards vis…. A kit-based SomaScan will make for easier customer access as well as higher margins, Taich said, projecting that the kits will have 60 percent-plus gross margins, roughly 10 points higher than the margins for the company's services business. Download as PDF Printable version.

Measure high- and low-abundance proteins confidently with superior sensitivity, high specificity, and proven reproducibility. See the science. Explore our services.

Canopy Canopy Public. One platform for discovery, validation, and development Move from discovery to validation quickly and efficiently on a single platform. Select Item. Daniel Katz, an instructor of medicine and cardiologist at Stanford Medicine, said that his group has used both platforms "extensively for a lot of different work and has found them both to be useful and to produce really interesting and scientifically exciting results. That SomaLogic's lackluster performance appears driven primarily by past business decisions as opposed to its technology suggests substantial upside for the company if it — and, assuming the merger goes through, Standard BioTools — is able to get its kit and broader commercial strategy right. Carey has been appointed as Chairman of the Board. SomaLogic has a long-term partnership with the Novartis Institutes for BioMedical Research, with Novartis taking an ownership stake in SomaLogic in as a part of the extension of their initial agreement. An Illumina-based readout won't be exclusive to SomaLogic. Read full article. Total cost synergies exclude non-cash, restructuring-related, transaction-related and other non-recurring costs for both Standard BioTools and SomaLogic. Interim Chief Executive Officer. But it isn't in our road map," he said.